Abstract
Background:
Metformin (MET) is a well-known pharmacologically significant hypoglycemic agent prescribed globally. In addition to its hypoglycemic effect, MET is reported to have anti-cancer properties due to its ability to induce apoptosis, halt the cell cycle, inhibit cell proliferation and metastasis, and induce changes in cell environment. Therefore, current study is designed to identify the in vitro effects of
MET on two breast cancer (BC) cell lines: triple-negative MDA-MB-231 and hormone receptors positive MCF7 cells.
Method:
The MDA-MB-231 and MCF7 cells were seeded in 96-well cell culture plates and adherent cells were treated with MET (5-70 x 10-3 moldm-3) and incubated at 24, 48 and 72 hours at 37 with 5% CO2 incubator. The cytotoxicity was assessed using Sulforhodamine B (SRB) assay following the respective incubation period. Half-maximal inhibitory concentrations (IC50) of MET for each cell line were calculated. Apoptosis was observed using ethidium bromide acridine orange staining with fluorescence microscopy.
Results:
The IC50 values after 24 hours of incubation for MDA-MB-231 and MCF7 were 306 x 10-3 moldm-3 and 227 x 10-3 moldm-3 respectively. The IC50 improved with
prolonged cell exposure indicating increased cytotoxicity with increased exposure duration. Fluorescence microscopy indicated the expression of apoptotic signals such as cytoplasmic blebbing and nuclear fragmentation at 24 hours of incubation in both cell lines at IC50 concentrations. These apoptotic signals were markedly elevated in concentrations above IC50.
Conclusions:
MET exerts promising cytotoxic effects and induces apoptosis against BC cells in vitro. MET is more cytotoxic to hormone receptor-positive cells than triple-negative cells in vitro. However, further studies are suggested to confirm the
anti-cancer effects exerted by MET on BC
Metformin (MET) is a well-known pharmacologically significant hypoglycemic agent prescribed globally. In addition to its hypoglycemic effect, MET is reported to have anti-cancer properties due to its ability to induce apoptosis, halt the cell cycle, inhibit cell proliferation and metastasis, and induce changes in cell environment. Therefore, current study is designed to identify the in vitro effects of
MET on two breast cancer (BC) cell lines: triple-negative MDA-MB-231 and hormone receptors positive MCF7 cells.
Method:
The MDA-MB-231 and MCF7 cells were seeded in 96-well cell culture plates and adherent cells were treated with MET (5-70 x 10-3 moldm-3) and incubated at 24, 48 and 72 hours at 37 with 5% CO2 incubator. The cytotoxicity was assessed using Sulforhodamine B (SRB) assay following the respective incubation period. Half-maximal inhibitory concentrations (IC50) of MET for each cell line were calculated. Apoptosis was observed using ethidium bromide acridine orange staining with fluorescence microscopy.
Results:
The IC50 values after 24 hours of incubation for MDA-MB-231 and MCF7 were 306 x 10-3 moldm-3 and 227 x 10-3 moldm-3 respectively. The IC50 improved with
prolonged cell exposure indicating increased cytotoxicity with increased exposure duration. Fluorescence microscopy indicated the expression of apoptotic signals such as cytoplasmic blebbing and nuclear fragmentation at 24 hours of incubation in both cell lines at IC50 concentrations. These apoptotic signals were markedly elevated in concentrations above IC50.
Conclusions:
MET exerts promising cytotoxic effects and induces apoptosis against BC cells in vitro. MET is more cytotoxic to hormone receptor-positive cells than triple-negative cells in vitro. However, further studies are suggested to confirm the
anti-cancer effects exerted by MET on BC
Original language | English |
---|---|
Pages | 121 |
Number of pages | 1 |
Publication status | Published - Apr 2024 |
Event | WONCA South Asia Region Conference 2024: in conjunction with Golden Jubilee Celebrations of the College of General Practitioners of Sri Lanka - Galle Face Hotel, Colombo, Sri Lanka Duration: 03 May 2024 → 05 May 2024 https://woncasar2024.com/about_woncasar2024.php |
Conference
Conference | WONCA South Asia Region Conference 2024 |
---|---|
Abbreviated title | Celebrating family medicine - nurturing our values across the region |
Country/Territory | Sri Lanka |
City | Colombo |
Period | 03/05/24 → 05/05/24 |
Internet address |